Literature DB >> 8839907

Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix.

E Pras, P H Willemse, H Boonstra, H Hollema, M A Heesters, B G Szabó, H W de Bruijn, J G Aalders, E G de Vries.   

Abstract

BACKGROUND: The feasibility of concurrent chemotherapy and radiotherapy for advanced primary carcinoma of the cervix was evaluated and the results were compared to historical controls. PATIENTS AND METHODS: In a single institution study, patients (n = 74) with primary cervical carcinoma received 3 cycles carboplatin/5-fluorouracil concurrent with radiotherapy followed by salvage hysterectomy (group I). Treatment results were compared with those of a historical control group (n = 39) (group II), treated similarly but without chemotherapy.
RESULTS: In group I median follow-up is 28 months (12-68+) and in group II 23 months (14-90+ months). The 5-year overall survival, progression-free survival and local recurrence free survival for group I and II are, respectively, 69% versus 38% (P < 0.003), 67% versus 38% (P < 0.005) and 84% versus 43% (P < 0.0001). Two patients in each group developed posttreatment enteritis.
CONCLUSIONS: Radiotherapy with concurrent carboplatin and 5-fluorouracil resulted in a better overall survival, disease free survival and local disease free survival compared to historical controls. The toxicity of this schedule did not exceed that of radiation alone in historical controls.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839907     DOI: 10.1093/oxfordjournals.annonc.a010641

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  [Radiotherapy and carboplatin in cervix cancer].

Authors:  J Dunst
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

2.  Health-related quality of life and late morbidity in concurrent chemoradiation and radiotherapy alone in patients with locally advanced cervical carcinoma.

Authors:  Maaike J Berveling; Johannes A Langendijk; Jannet C Beukema; Marian J E Mourits; Anna K L Reyners; Elisabeth Pras
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.